MedTrace Logo

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

NCT00626392 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 277

Last updated 2009-09-02

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.

Conditions

Interventions

DRUG

niacin extended-release (NER)

Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

DRUG

aspirin (ASA)

325 mg tablets administered once daily

DRUG

aspirin placebo (ASA Pbo)

Tablets administered once daily

Sponsors & Collaborators

Principal Investigators

  • Roopal Thakkar, MD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00626392 on ClinicalTrials.gov